Lv5
1600 积分 2023-06-29 加入
Machine learning and artificial intelligence for the diagnosis of infectious diseases in immunocompromised patients
9个月前
已完结
[Polatuzumab vedotin, bendamustine, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma, including the outcome as a bridging treatment to CAR-T cell therapy or allogeneic hematopoietic stem cell transplant]
1年前
已关闭
[Polatuzumab vedotin, bendamustine, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma, including the outcome as a bridging treatment to CAR-T cell therapy or allogeneic hematopoietic stem cell transplant]
1年前
已关闭
[Polatuzumab vedotin, bendamustine, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma, including the outcome as a bridging treatment to CAR-T cell therapy or allogeneic hematopoietic stem cell transplant]
1年前
已关闭
Integrating CAR-T cell therapy into the management of DLBCL: what we are learning
1年前
已完结
[The Latest Research Progress of Selinexor in the Treatment of Non-Hodgkin Lymphoma --Review]
1年前
已完结
XPO1-Mediated mRNA Export of Genome Maintenance Regulators Drives Chemotherapy Resistance in Aggressive Lymphoma
1年前
已完结
Second-line treatment of diffuse large B‐cell lymphoma: Evolution of options
1年前
已完结
Furmonertinib and intrathecal pemetrexed chemotherapy rechallenges osimertinib-refractory leptomeningeal metastasis in a non-small cell lung cancer patient harboring EGFR20 R776S, C797S, and EGFR21 L858R compound EGFR mutations: a case report
1年前
已完结
Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study
1年前
已完结
The optimal ratio of endoscope-sheath diameter with negative-pressure ureteral access sheath: an in vitro research
皖公网安备34019202002308
